46P - Antitumor efficacy of the double suicide genes in lung cancer cells

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Basic Science
Lung and other Thoracic Tumours
Translational Research
Presenter Cheng Shen
Citation Annals of Oncology (2015) 26 (suppl_1): 10-14. 10.1093/annonc/mdv045
Authors C. Shen, G. Che
  • Thoracic Surgery, West China Hospital, Huaxi, Sichuan University, 610041 - Chengdu/CN

Abstract

Aim/Background

To construct a recombinant adenovirus containing CDglyTK double suicide genes and evaluate the antitumor efficacy of the double suicide genes driven by kinase domain insert containing receptor (KDR) promoter on lung cancer cells.

Methods

A double suicide gene system with the KDR promoter, pcDNA3-KDRp-CDglyTK, was constructed and transfected into lung cancer cell lines L9981 and NL9980, and human hepatocellular carcinoma cell line HepG2. The efficiency and specificity of the double suicide gene system were assayed by in vivo xenograft studies. Different injection techniques in vivo antitumor effects had also been compared.

Results

The transgenic CD and TK genes were only expressed in L9981 and NL9980 but not in HepG2 cells. It also showed the evident tumor inhibiting ability by intratumoral injection than tail vein injection in the highly metastatic human large cell lung cancer cell line L9981, which displayed higher inhibitory rate than in the less metastatic human lung cell line NL9980. But no effect was shown on the tumors from the hepatic carcinoma HepG2 cells.

Conclusions

The KDR promoter is capable of regulating a double suicide gene system in human lung cancer cells, thus providing laboratory evidence to develop a gene therapy approach against various cancers. Expression of CDglyTK genes under the control of KDR promotor represents a new strategy for effective gene therapy of tumors expressing intrinsic KDR.

Disclosure

All authors have declared no conflicts of interest.